Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 3, 2006, Pages 512-515

  Gama, Clarissa Severino ^a   Salvador, Mirian ^b   Andreazza, Ana Cristina ^b   Kapczinski, Flavio ^a   Silva Belmonte de Abreu, Paulo ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF CAXIAS DO SUL   (Brazil)

Author keywords

Antioxidant enzymes; Clozapine; Haloperidol; Peroxidative damage; Schizophrenia

Indexed keywords

ANTIOXIDANT; CLOZAPINE; HALOPERIDOL; OXIDIZING AGENT; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPID PEROXIDATION; LONG TERM CARE; MALE; MENTAL PATIENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 33646479818     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.009     Document Type: Article

References (36)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psych 26 5 (2002) 995-1005
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53 1 (2003) 56-64
3. Azevedo M.H., Soares M.J., Coelho I., Dourado A., Valente J., Macedo A., et al. Using consensus OPCRIT diagnoses. An efficient procedure for best-estimate lifetime diagnoses. Br J Psychiatry 175 (1999) 154-157
4. Bilder R.M., Goldman J., Volavka P., Czobor P., Hoptman B., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. J Psychiatry 159 (2002) 1018-1028
5. Craddock M., Asherson P., Owen M.J., Williams J., McGuffin P., and Farmer A.E. Concurrent validity of the OPCRIT diagnostic system. Comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses. Br J Psychiatry 169 1 (1996) 58-63
6. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., and Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6 1 (2001) 66-73
7. Ingebrigtsen T., Waterloo K., Jacobsen E.A., Langbakk B., and Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery 45 (1999) 468-475
8. Kane J., Honigfeld G., Singer J., Meltzer H., and Clorazil Collaborative Study Group. Clozapine for the treatment resistent schizophrenic: a double-blind comparison with clorpromazine. Arch Gen Psychiatry 45 (1988) 789-796
9. Kasperczyk S., Birkner E., Kasperckyk A., and Zalejka-Fiolka J. Activity of superoxide dismutase and catalase in people protractedly exposed to lead compounds. Ann Agric Environ Med 11 (2004) 291-296
10. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58 1 (2002) 1-10
11. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Gonçalves C.A., Fonseca M., et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 35 1 (2001) 11-14
12. Lohr J.B., and Browning J.A. Free radical involvement in neuropsychiatry illnesses. Psychopharmacol Bull 31 1 (1995) 159-165
13. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19 1 (1996) 1-17
14. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., and Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43 9 (1998) 674-679
15. Mahadik S.P., Evans D., and Lal H. Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psych 25 (2001) 463-493
16. McCreadie R.G., MacDonald E., Wiles D., Campbell G., and Paterson J.R. The Nithsdale Schizophrenia Surveys: XIV. Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry 167 5 (1995) 610-617
17. McEvoy J.P., Hogarty G.E., and Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Ach Gen Psychiatry 48 (1991) 739-745
18. McGuffin P., Farmer A., and Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48 8 (1991) 764-770
19. Melamed Y., Sirota P., Dicker D.R., and Fishman P. Superoxide anion production by neutrophils derived from peripheral blood of schizophrenic patients. J Psychiatr Res 77 1 (1998) 29-34
20. Mirsa H.P., and Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 217 10 (1972) 3170-3175
21. Mohammadi M.R., and Akhondzadeh S. Schizophrenia: etiology and pharmacotherapy. Idrugs 4 10 (2001) 1167-1172
22. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., and Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 19 1 (1996) 19-26
23. Parikh V., Khan M.M., and Mahadik S.P. Differencitial effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37 (2003) 43-51
24. Petronijevic N.D., Micic D.V., Duricic B., Marinkovic D., and Paunovic V.R. Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia. Prog Neuropsychopharmacol Biol Psych 27 3 (2003) 431-440
25. Reddy R.D., and Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 55 1-2 (1996) 33-43
26. Reddy R., Keshavan M., and Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62 3 (2003) 205-212
27. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., and Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372 1-2 (2004) 157-160
28. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6 (2001) 445-449
29. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 158 2 (2001) 140-145
30. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45 (1999) 1508-1511
31. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem J 99 5 (1966) 667-676
32. Yao J.K., Reddy R., McElhinny L.G., and van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32 1 (1998) 1-8
33. Yao J.K., Reddy R., McElhinny L.G., and van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 32 6 (1998) 385-391
34. Zelko I.N., Mariani T.J., and Folz R.J. Superoxide dismutase multigene family: a comparision of the Cu-Zn-Sod (Sod1), Mn-Sod (Sod2) and EC-Sod (Sod3) gene structures, evolution, and expression. Free Radic Biol Med 33 3 (2002) 337-349
35. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., and Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. J Psychiatr Res 117 1 (2003) 85-88
36. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., and Shen Y.C. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 23 2 (2003) 128-131